Patrys LimitedASX: PAB

RLS-2202 Phase 1a Trial Advances to Cohort 2

Oct 21, 2026 at 5:18 PM EDT · Issued by Patrys Limited via ASX

Filed with ASX · Oct 21, 2026 at 5:18 PM EDT · 3 pages · English

On 6ix: 6ix.com/news/rls-2202-phase-1a-trial-advances-to-cohort-2-1

Release

22 October 2026 RLS-2202 PHASE 1A TRIAL ADVANCES TO COHORT 2 HIGHLIGHTS • Safety Review Committee has completed its review of Cohort 1 safety and pharmacokinetic data and determined the dose for Cohort 2 progression. • Recruitment for Cohort 2 is expected to commence shortly. • Patrys remains...

Patrys Limited on 6ix

Story so far

Patrys Completes Cohort 1 Dosing and Follow-UpSep 28, 2026

Earlier from Patrys

Investor PresentationOct 12
Investor WebinarOct 5
Date of AGM and Closing Date for Director NominationsOct 5
Notification of cessation of securities - PABSep 30
Patrys Completes Cohort 1 Dosing and Follow-UpSep 28

Later from Patrys

Appendix 4C - Quarterly - 30 September 2026Oct 28
Notice of Annual General Meeting/Proxy FormOct 29
Letter to Shareholders - Annual General MeetingOct 29

All Patrys news releases

Follow Patrys into a list and get an email when it puts out news.

Follow Patrys